Endocrine Pharmacology Practice Questions

Q: A 45-year-old man with type 2 diabetes develops tender hemorrhagic bullae on both legs after starting empagliflozin. Blood glucose is well-controlled. Most appropriate management is:

Stop empagliflozin. **Stop empagliflozin** * Empagliflozin, an **SGLT2 inhibitor**, is associated with an increased risk of **bullous pemphigoid**, especially in patients with diabetes. The presentation of **tender hemorrhagic bullae** strongly suggests this adverse drug reaction [1]. * Discontinuation of the offending drug is the **most appropriate initial management** to prevent further lesion development and allow for resolution [1]. *Add topical antibiotics* * Topical antibiotics might be used for **secondary infection** of the bullae, but they do not address the underlying cause of the condition, which is a drug-induced reaction. * Stopping the causative agent is paramount; treating symptoms alone without removing the trigger is insufficient. *Switch to another SGLT2 inhibitor* * Since the bullae are likely an **adverse effect** of the SGLT2 inhibitor class (specifically, association with bullous pemphigoid), switching to another drug within the same class (another SGLT2 inhibitor) would likely result in the recurrence or persistence of the adverse reaction. * Cross-reactivity is common among drugs within the same pharmacological class, especially for immune-mediated skin reactions. *Continue empagliflozin with wound care* * Continuing the drug that is causing a severe skin reaction like bullous pemphigoid is **contraindicated** and would lead to worsening of the condition and potential complications. * While wound care is important for managing the lesions, it does not address the underlying cause, and continuing the medication would prevent healing and increase patient morbidity.

Q: Which of the following drugs can decrease the size of the prostate?

Finasteride. ***Finasteride***- **Finasteride** is a **5-alpha-reductase inhibitor** that blocks the conversion of testosterone to dihydrotestosterone (DHT), thereby reducing the size of the prostate. [1]- **DHT** is primarily responsible for the growth and enlargement of the prostate gland in benign prostatic hyperplasia (BPH).*Sildenafil*- **Sildenafil** is a **phosphodiesterase-5 (PDE5) inhibitor** used to treat erectile dysfunction and pulmonary hypertension.- It acts by increasing blood flow to the penis and does not affect prostate size.*Tamsulosin*- **Tamsulosin** is an **alpha-1 adrenergic antagonist** that relaxes smooth muscles in the prostate and bladder neck, improving urine flow.- While it alleviates symptoms of BPH, it does not reduce the actual size of the prostate gland. [2]*Prazosin*- **Prazosin** is also an **alpha-1 adrenergic antagonist** used to treat hypertension and, off-label, BPH symptoms by relaxing smooth muscles.- Similar to tamsulosin, it improves urine flow but does not decrease prostate volume. [2]

Q: A diabetic patient presented with uncontrolled blood sugar level. He has history of pancreatitis and family history of urinary bladder carcinoma. He does not want to take injectable drugs. Which of the following drug can be added to control his blood sugar?

Sitagliptin. ***Sitagliptin*** - Sitagliptin is a **DPP-4 inhibitor** that enhances endogenous incretin hormones, leading to glucose-dependent insulin secretion without causing weight gain. - It is **safe in patients with history of pancreatitis** and has **no association with bladder cancer risk**. - It is an **oral medication**, which aligns with the patient's preference to avoid injectable drugs. - This is the **most appropriate choice** given all the patient's contraindications and preferences. *Canagliflozin* - Canagliflozin is an **SGLT2 inhibitor** that increases glucose excretion in the urine and provides cardiovascular and renal benefits. - It is **oral** and **safe in pancreatitis** with **no bladder cancer association**. - However, it is not the best first choice compared to DPP-4 inhibitors in this clinical scenario, though it would be an acceptable alternative. *Pioglitazone* - Pioglitazone is a **thiazolidinedione** that improves insulin sensitivity but is associated with an **increased risk of bladder carcinoma**. - It is **contraindicated in this patient** due to his family history of urinary bladder carcinoma. - It can also cause weight gain and fluid retention. *Liraglutide* - Liraglutide is a **GLP-1 receptor agonist** that is highly effective for glycemic control and weight loss [2]. - However, it is an **injectable drug** [1], which goes against the patient's preference. - Additionally, **GLP-1 agonists are relatively contraindicated in patients with history of pancreatitis** due to risk of pancreatitis exacerbation [1], [2].

Q: All of the following statements about insulin Afrezza are true except:

Used in combination with short acting insulin. ***Used in combination with short acting insulin*** - Insulin Afrezza is a **rapid-acting inhaled insulin** that is typically used *before meals* as a prandial insulin. - It is used **in combination with a long-acting (basal) insulin**, not short-acting insulin, to manage blood glucose levels. - Afrezza itself IS a rapid-acting insulin, so combining it with another short-acting insulin would be redundant. *Inhalational preparation of insulin* - Afrezza is an **inhaled insulin preparation**, delivered via a small, hand-held inhaler device. - This delivery method offers a **needle-free alternative** for mealtime insulin administration. *Requires multiple inhalations per administration* - Each dose of Afrezza often requires **multiple inhalations** to deliver the prescribed insulin unitage, depending on the cartridge size (4, 8, or 12 units). - This can be perceived as less convenient than a single injection for some patients. *Not a substitute for long-acting injectable insulin* - Afrezza is an **alternative to rapid-acting injectable insulin** for mealtime glucose control. - However, patients still require **long-acting basal insulin** (such as insulin glargine or detemir), which is usually administered via injection, to manage blood glucose between meals and overnight. - Afrezza does NOT replace the need for basal insulin therapy.

Q: A patient with bronchial asthma develops osteoporosis. Most likely mechanism?

Chronic steroid use. ***Chronic steroid use*** - **Glucocorticoids**, commonly used in the treatment of bronchial asthma, can directly inhibit **osteoblast activity** and promote **osteoclast activity**, leading to bone loss [1]. - They also reduce intestinal **calcium absorption** and increase **renal calcium excretion**, further disrupting calcium homeostasis and contributing to osteoporosis [1]. *Calcium malabsorption* - While **malabsorption syndromes** can cause osteoporosis, asthma itself does not directly lead to primary calcium malabsorption. - Steroids used in asthma treatment can *contribute* to reduced calcium absorption, but the primary mechanism of steroid-induced osteoporosis involves broader effects on bone metabolism, not solely malabsorption [1]. *Inflammatory mediators* - **Inflammatory mediators** associated with asthma may play a role in bone density loss, but their direct impact is less significant and less common than the effects of chronic steroid use [2]. - While chronic inflammation can indirectly affect bone remodeling, it is not the most likely or direct mechanism for osteoporosis in this clinical scenario compared to steroid exposure [1]. *Physical inactivity* - **Physical inactivity** can contribute to osteoporosis due to reduced mechanical loading on bones, but it is not a direct or primary cause specific to bronchial asthma [3]. - While severe asthma may lead to some activity limitation, the primary mechanism linking asthma treatment to osteoporosis is typically medication-related, rather than lifestyle factors alone.

Q: A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?

Fluid retention. ***Fluid retention***- **Pioglitazone**, a thiazolidinedione (TZD), commonly causes **fluid retention** or edema [1].- This fluid retention can **exacerbate heart failure** symptoms and lead to cardiac decompensation, especially in patients with pre-existing heart conditions [1].*Hepatotoxicity*- While TZDs like pioglitazone have been associated with **liver dysfunction** in some cases, significant hepatotoxicity is rare and usually not the primary concern or most common serious side effect [1].- **Regular monitoring of liver enzymes** is recommended, but fluid retention leading to heart failure exacerbation is a more immediate and severe risk in this patient profile.*Pulmonary fibrosis*- **Pulmonary fibrosis** is not a known or common complication directly associated with pioglitazone use.- This complication is typically linked to other medications or systemic diseases.*Hypokalemia*- **Hypokalemia**, or low potassium levels, is generally not a direct side effect of pioglitazone.- Electrolyte imbalances associated with heart failure or diuretic use, rather than pioglitazone itself, are more likely causes of hypokalemia.

Q: Which drug reduces postprandial hyperglycemia in type 2 diabetes?

Acarbose. ***Acarbose*** - **Acarbose** is an **alpha-glucosidase inhibitor** that works by delaying the digestion and absorption of carbohydrates in the gut. - This delay in carbohydrate absorption directly reduces the postprandial (after-meal) rise in blood glucose levels. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione** that improves insulin sensitivity primarily in muscle and adipose tissue. - While it lowers overall blood glucose, its main effect is not specifically on postprandial hyperglycemia. *Glyburide* - **Glyburide** is a **sulfonylurea** that stimulates the pancreas to release more insulin. - It lowers blood glucose by increasing insulin secretion, which impacts both fasting and postprandial levels, but its primary action isn't specific to rapid postprandial peaks. *Metformin* - **Metformin** is a **biguanide** that primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. - While it lowers both fasting and postprandial glucose, its main mechanism is not directly targeting the immediate digestion of carbohydrates after a meal.

Q: Continuous GnRH therapy is used in All EXCEPT.

Male infertility. ***Male infertility*** - **Pulsatile GnRH therapy** is used to stimulate gonadotropin secretion and subsequent testosterone production in hypogonadotropic hypogonadism, which can cause male infertility. - **Continuous GnRH therapy** causes downregulation of GnRH receptors leading to suppression of gonadotropin release, which would worsen male infertility. *Precocious puberty* - Continuous GnRH therapy (GnRH agonists) is used to suppress the **pituitary-gonadal axis**, effectively stopping the progression of precocious puberty. - By continuously stimulating GnRH receptors, it leads to their **desensitization and downregulation**, preventing the pulsatile release of LH and FSH. *Prostate cancer* - Continuous GnRH therapy (GnRH agonists) is used for **androgen deprivation therapy**, suppressing testosterone production, which fuels prostate cancer growth. - This effectively creates a chemical castration effect by **downregulating GnRH receptors** on pituitary gonadotrophs. *Endometriosis* - Continuous GnRH therapy (GnRH agonists) is used to induce a **hypoestrogenic state**, which helps shrink endometrial implants. - By continuously stimulating GnRH receptors, it leads to their **desensitization and downregulation**, reducing estrogen production from the ovaries.

Q: A 55-year-old patient presents to the clinic with a history of hyperglycemia and has had positive urine glucose tests on 2 separate occasions in the last six months. The patient has been diagnosed with type 2 diabetes mellitus. The physician is considering various medications to manage the patient’s condition and prevent potential complications including renal involvement. Which of the following drugs will not delay renal involvement?

Hydrochlorothiazide. ***Hydrochlorothiazide*** - **Hydrochlorothiazide** is a thiazide diuretic primarily used for hypertension and edema, and it does not have direct renal protective effects in the context of diabetic nephropathy; it may even worsen glycemic control. - While it lowers blood pressure, its mechanism of action does not address the underlying **glomerular hyperfiltration** or inflammation that contribute to diabetic renal damage. *Angiotensin receptor blockers* - **Angiotensin receptor blockers (ARBs)**, such as losartan or valsartan, are renoprotective as they reduce **intraglomerular pressure** and decrease proteinuria by blocking the effects of angiotensin II. - They are a cornerstone in managing **diabetic nephropathy** and are known to slow the progression of renal disease. *Finerenone* - **Finerenone** is a selective, non-steroidal mineralocorticoid receptor antagonist that has been shown to reduce the risk of kidney disease progression and cardiovascular events in patients with chronic kidney disease and type 2 diabetes. - It works by blocking the harmful effects of **aldosterone**, including inflammation and fibrosis, which contribute to renal damage. *SGLT2 inhibitors* - **SGLT2 inhibitors**, like empagliflozin or canagliflozin, reduce glucose reabsorption in the kidneys, leading to glucose excretion in the urine, and have demonstrated significant **renoprotective benefits** independent of their glucose-lowering effects. - Their mechanisms involve reducing **glomerular hyperfiltration**, decreasing proteinuria, and mitigating inflammation and fibrosis, thereby delaying the progression of diabetic kidney disease.

Q: Which of the following anti-diabetic drugs is associated with increased risk of UTI?

Dapagliflozin. ***Dapagliflozin*** - **Dapagliflozin** is a **sodium-glucose cotransporter-2 (SGLT2) inhibitor** that works by increasing glucose excretion in the urine. - This increased urinary glucose provides a favorable environment for bacterial growth, leading to a higher risk of **urinary tract infections (UTIs)** and **genital mycotic infections**. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione** that improves insulin sensitivity in peripheral tissues. - Its primary side effects include **fluid retention**, **weight gain**, and increased risk of **bone fractures** and **heart failure**, not UTIs. *Metformin* - **Metformin** is a **biguanide** that reduces hepatic glucose production and improves insulin sensitivity. - Its most common side effects are **gastrointestinal disturbances** like nausea, diarrhea, and abdominal pain, and it does not typically increase the risk of UTIs. *Sitagliptin* - **Sitagliptin** is a **dipeptidyl peptidase-4 (DPP-4) inhibitor** that enhances endogenous incretin hormones, leading to increased insulin release and reduced glucagon secretion. - It is generally well-tolerated, with side effects that can include **nasopharyngitis** and headache, but it is not associated with an increased risk of UTIs.

Question 1

A 45-year-old man with type 2 diabetes develops tender hemorrhagic bullae on both legs after starting empagliflozin. Blood glucose is well-controlled. Most appropriate management is:

Accepted Answer

Stop empagliflozin

Answer

Add topical antibiotics

Answer

Switch to another SGLT2 inhibitor

Answer

Continue empagliflozin with wound care

Question 2

Which of the following drugs can decrease the size of the prostate?

Accepted Answer

Finasteride

Answer

Sildenafil

Answer

Tamsulosin

Answer

Prazosin

Question 3

A diabetic patient presented with uncontrolled blood sugar level. He has history of pancreatitis and family history of urinary bladder carcinoma. He does not want to take injectable drugs. Which of the following drug can be added to control his blood sugar?

Accepted Answer

Sitagliptin

Answer

Canagliflozin

Answer

Pioglitazone

Answer

Liraglutide

Question 4

All of the following statements about insulin Afrezza are true except:

Accepted Answer

Used in combination with short acting insulin

Answer

Inhalational preparation of insulin

Answer

Requires multiple inhalations per administration

Answer

Not a substitute for long-acting injectable insulin

Question 5

A patient with bronchial asthma develops osteoporosis. Most likely mechanism?

Accepted Answer

Chronic steroid use

Answer

Calcium malabsorption

Answer

Inflammatory mediators

Answer

Physical inactivity

Question 6

A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?

Accepted Answer

Fluid retention

Answer

Hepatotoxicity

Answer

Pulmonary fibrosis

Answer

Hypokalemia

Question 7

Which drug reduces postprandial hyperglycemia in type 2 diabetes?

Accepted Answer

Acarbose

Answer

Pioglitazone

Answer

Glyburide

Answer

Metformin

Question 8

Continuous GnRH therapy is used in All EXCEPT.

Accepted Answer

Male infertility

Answer

Precocious puberty

Answer

Prostate cancer

Answer

Endometriosis

Question 9

A 55-year-old patient presents to the clinic with a history of hyperglycemia and has had positive urine glucose tests on 2 separate occasions in the last six months. The patient has been diagnosed with type 2 diabetes mellitus. The physician is considering various medications to manage the patient’s condition and prevent potential complications including renal involvement. Which of the following drugs will not delay renal involvement?

Accepted Answer

Hydrochlorothiazide

Answer

Angiotensin receptor blockers

Answer

Finerenone

Answer

SGLT2 inhibitors

Question 10

Which of the following anti-diabetic drugs is associated with increased risk of UTI?

Accepted Answer

Dapagliflozin

Answer

Pioglitazone

Answer

Metformin

Answer

Sitagliptin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?